Short answer
Bicara Therapeutics Inc. (BCAX) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$56M
- −52.6% YoY
- EPS (diluted)
- −$0.93
- −36.8% YoY
Source: XBRL data from the Bicara Therapeutics Inc. (BCAX) Q1 2026 10-Q on SEC EDGAR. USD.
Bicara Therapeutics Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales or other revenue generated
- Net loss $56.2M vs $36.8M YoY; operating loss $60.2M vs $41.8M
- R&D expense $47.5M vs $34.3M; manufacturing and process development highest at $23.2M
- Cash, equivalents and marketable securities $539.8M; February offering added $161.8M net proceeds
- Runway into first half of 2029; substantial additional capital expected for clinical development and commercialization enabling work
Risk Factors
- Newly triggered February 2026 Offering: 8,581,250 shares and warrants generated approximately $161.8 million net proceeds
- Financial runway through first half of 2029 depends on operating assumptions that may prove incorrect
- Clinical-development risk: FORTIFI-HN01 Phase 2/3 trial may face regulatory delays, holds, or inconclusive efficacy
- Competitive risk: Keytruda and multiple HNSCC programs could establish stronger market positions before ficerafusp alfa launches
- Concentration risk: majority of $539.8 million cash, equivalents, and marketable securities held at institutions with uninsured deposits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bicara Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.